Steven E Coutre
Overview
Explore the profile of Steven E Coutre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
5923
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Coutre S, Barnett C, Osiyemi O, Hoda D, Ramgopal M, Fort A, et al.
Open Forum Infect Dis
. 2022 May;
9(5):ofac104.
PMID: 35493119
Background: Few therapies are approved for hospitalized patients with severe coronavirus disease 2019 (COVID-19). Ibrutinib, a once-daily Bruton tyrosine kinase inhibitor, may mitigate COVID-19-induced lung damage by reducing inflammatory cytokines....
2.
Shanafelt T, Wang X, Hanson C, Paietta E, OBrien S, Barrientos J, et al.
Blood
. 2022 Apr;
140(2):112-120.
PMID: 35427411
Herein, we present the long-term follow-up of the randomized E1912 trial comparing the long-term efficacy of ibrutinib-rituximab (IR) therapy to fludarabine, cyclophosphamide, and rituximab (FCR) and describe the tolerability of...
3.
Wang X, Hanson C, Tschumper R, Lesnick C, Braggio E, Paietta E, et al.
Blood
. 2021 Aug;
138(26):2810-2827.
PMID: 34407545
E1912 was a randomized phase 3 trial comparing indefinite ibrutinib plus 6 cycles of rituximab (IR) to 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) in untreated younger patients with...
4.
Ladha A, Hui G, Cheung E, Berube C, Coutre S, Gotlib J, et al.
Leuk Lymphoma
. 2021 Jan;
62(6):1510-1513.
PMID: 33491527
No abstract available.
5.
Ghia P, Coutre S, Cheson B, Barrientos J, Hillmen P, Pettitt A, et al.
Haematologica
. 2020 Oct;
105(10):e519.
PMID: 33054096
No abstract available.
6.
Lancet J, Moseley A, Coutre S, DeAngelo D, Othus M, Tallman M, et al.
Blood Adv
. 2020 Apr;
4(8):1683-1689.
PMID: 32330241
High-risk acute promyelocytic leukemia (APL) remains a therapeutic challenge, with higher associated rates of early mortality and relapse than standard-risk APL. All-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) is...
7.
Byrd J, Furman R, Coutre S, Flinn I, Burger J, Blum K, et al.
Clin Cancer Res
. 2020 Mar;
26(15):3918-3927.
PMID: 32209572
Purpose: The safety and efficacy of ibrutinib, a once-daily Bruton's tyrosine kinase (BTK) inhibitor, in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was demonstrated in this phase Ib/II study. Extended follow-up...
8.
Coutre S, Flinn I, de Vos S, Barrientos J, Schreeder M, Wagner-Johnson N, et al.
Hemasphere
. 2019 Nov;
2(3):e39.
PMID: 31723767
Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activity in...
9.
Burger J, Barr P, Robak T, Owen C, Ghia P, Tedeschi A, et al.
Leukemia
. 2019 Oct;
34(3):787-798.
PMID: 31628428
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to...
10.
Kipps T, Fraser G, Coutre S, Brown J, Barrientos J, Barr P, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Aug;
19(11):715-722.e6.
PMID: 31447270
Background: Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia...